Latest KFF Health News Stories
The Market for Biosimilars Is Funky. The Industry Thinks PBMs Are To Blame
Over the past year there’s been movement to rein in the three big PBMs, which face little regulation though they help set drug prices and drug choices for 80 percent of Americans and their doctors. The House voted Dec. 11, 320-71, for legislation that would require the PBMs to change some of the ways they […]
Millions of Dollars Flow From Pharma to Patient Advocacy Groups
Pharma money is all over the place — in universities, companies doing continuing medical education for doctors and in prominent patient advocacy organizations that are household names across America. Public Citizen, a consumer advocacy nonprofit, reports today that between 2010 and 2022, the drug industry’s main lobbying group and member companies provided at least $6 […]
Colorado culpa a Biden y a farmacéuticas por retrasar importaciones de medicamentos de Canadá
Los consumidores estadounidenses pagan algunos de los precios más altos del mundo por medicamentos de marca. En Canadá, el gobierno controla los precios.
Programas ponen los medicamentos sin usar en manos de pacientes que los necesitan
Recogen de centros de salud, residentes, farmacias o prisiones los medicamentos sin abrir y sin caducar que se acumulan cuando los pacientes son dados de alta, cambian de medicina o mueren, y los redistribuyen a pacientes vulnerables.
Colorado Blames Biden Team and Drugmakers for Delaying Canadian Imports
Colorado officials say they haven’t been able to stand up a program to import drugs from Canada because of drugmaker opposition — and the Biden administration’s inaction.
Readers Slam Hospital Monopolies and Blame the Feds for Understaffed Nursing Homes
KFF Health News gives readers a chance to comment on a recent batch of stories.
These Programs Put Unused Prescription Drugs in the Hands of Patients in Need
States and counties look to expand programs that accept donations of unused surplus drugs from places like nursing homes and hospitals and redistribute them to low-income and uninsured residents.
Watch and Listen: Opioid Settlement Case Triggers Protests Outside the High Court
The Supreme Court heard arguments over whether the Sacklers, the family behind Purdue Pharma — which marketed OxyContin — could claim immunity from future lawsuits without claiming bankruptcy.
Colorado Says Drug Industry Blocked Its Canada Dreams – And Biden Hasn’t Helped
Colorado’s leaders had grand plans to import cheaper medicines from Canada, after the Trump administration issued rules in 2020 allowing states to try it. But officials in Denver say they’ve been stymied by opposition from drugmakers — as well as the Biden administration’s inaction on the policy. That’s according to a Dec. 1 report we […]
Many Autoimmune Disease Patients Struggle With Diagnosis, Costs, Inattentive Care
Despite the prevalence of autoimmune conditions, like the thyroid disease Hashimoto’s, sometimes finding help can prove frustrating as well as expensive. There are often no definitive diagnostic tests, so patients may rack up big bills as they search for confirmation of their condition and for treatment options.
Health Care Is Front and Center as DeSantis and Newsom Go Mano a Mano
Florida’s Republican Gov. Ron DeSantis and California’s Democratic Gov. Gavin Newsom will square off in a first-of-its-kind debate on Nov. 30. KFF Health News compared the political rivals’ health care positions, showing how their policies have helped — or hindered — the health of their states’ residents.
Evolving Overdose Crisis Shakes Previously Effective Treatments
The prevalence of synthetic drugs is undercutting a previously effective and widely embraced opioid use disorder treatment tactic. Now, the model pioneered in Vermont a decade ago and adopted at sites nationwide, especially in hard-to-reach rural areas, is being forced to evolve.
Journalists Delve Into Open Enrollment, School Nurse Shortages, and More
KFF Health News and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
Beyond Insulin: Medi-Cal Expands Patient Access to Diabetes Supplies
California’s Medicaid program is making it easier for people with diabetes to obtain the supplies and equipment they need to manage their blood sugar, partly by relaxing preauthorization requirements that can cause life-threatening delays.
Biden Administration’s Limit on Drug Industry Middlemen Backfires, Pharmacists Say
A rule taking effect Jan. 1 was intended to stop one set of abuses by pharmacy benefit managers, or PBMs, but some pharmacists say it’s enabling these price brokers to simply do new things unfairly.
A New RSV Shot Could Help Protect Babies This Winter — If They Can Get It in Time
Supply problems, a high price tag, and bureaucratic obstacles are slowing the distribution of a therapy that can protect infants from the respiratory syncytial virus. That will leave them unnecessarily at risk of hospitalization this winter, pediatricians fear.
US to Cover HIV Prevention Drugs for Older Americans to Stem Spread of the Virus
The government has proposed that Medicare fully cover preexposure prophylaxis drugs that prevent HIV, a change that could help America catch up with nations in Europe and Africa that are on track to end new infections decades before the U.S. under its current approach.
Prevención del VIH: proponen que Medicare cubra PrEP para adultos mayores
Según el plan de la administración Biden, Medicare cubriría el costo total de los medicamentos de profilaxis previa a la exposición, que previenen la transmisión del VIH.
An Arm and a Leg: John Green vs. Johnson & Johnson (Part 2)
The high price of lifesaving tuberculosis drugs makes them inaccessible to many who need them most. On this episode of “An Arm and a Leg,” hear how a decades-long global fight to reform drug patents is helping to lower the cost.
A New Era of Vaccines Leaves Old Questions About Prices Unanswered
The CDC’s RSV vaccination recommendations beg the question: How much should an immunization that will possibly be given to millions of Americans cost to be truly valuable?
